Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446921 | 0.89 | GPBAR1 (0.60) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13293168 | 0.89 | GPBAR1 (0.60) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL14398336 | 0.89 | GPBAR1 (0.60) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13293189 | 0.84 | GPBAR1 (0.56) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL5448725 | 0.83 | PTPN1 (0.68) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13098042 | 0.83 | PTPN1 (0.68) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13293181 | 0.83 | PTPN1 (0.68) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL14374360 | 0.83 | PTPN1 (0.56) | GPBAR1LMNANT5EUSP2HIF1A | |
| SCHEMBL23626100 | 0.83 | EGLN2 (0.67) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13910807 | 0.83 | GPBAR1 (0.51) | GPBAR1LMNANT5ESMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144688-A1 | 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids | ADVANCED LIFE SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144688-A1 | 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids | BRCA1, PGF, LSS | EGLN2 1377/4885EGLN1 717/4885EGLN3 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.